KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Accumulated Expenses: 2017-2025

Historic Accumulated Expenses for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $1.2 billion.

  • Moderna's Accumulated Expenses fell 14.39% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year decrease of 14.39%. This contributed to the annual value of $1.4 billion for FY2024, which is 20.63% down from last year.
  • As of Q3 2025, Moderna's Accumulated Expenses stood at $1.2 billion, which was up 19.35% from $987.0 million recorded in Q2 2025.
  • Moderna's Accumulated Expenses' 5-year high stood at $2.2 billion during Q3 2023, with a 5-year trough of $753.0 million in Q1 2021.
  • For the 3-year period, Moderna's Accumulated Expenses averaged around $1.4 billion, with its median value being $1.4 billion (2024).
  • As far as peak fluctuations go, Moderna's Accumulated Expenses skyrocketed by 1,268.59% in 2021, and later plummeted by 38.13% in 2024.
  • Moderna's Accumulated Expenses (Quarterly) stood at $1.5 billion in 2021, then surged by 42.73% to $2.1 billion in 2022, then fell by 14.42% to $1.8 billion in 2023, then fell by 20.63% to $1.4 billion in 2024, then declined by 14.39% to $1.2 billion in 2025.
  • Its Accumulated Expenses was $1.2 billion in Q3 2025, compared to $987.0 million in Q2 2025 and $1.0 billion in Q1 2025.